A new assay for the determination of factor XII in plasma using a chromogenic substrate and a selective inhibitor of plasma kallikrein.
A new chromogenic assay for factor XII in plasma was designed by the use of the soluble activator Kalliplastin, the substrate H-D-HHT-Gly-Arg-pNA and a synthetic inhibitor of plasma kallikrein (Pefabloc PK). The assay was carried out in one and the same cuvette and did not require factor XII-deficient plasma. There was a good correlation between F XII coagulant and amidolytic assays.
Stürzebecher
J
J
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, G.D.R.
Svendsen
L
L
Eichenberger
R
R
Markwardt
F
F
D001550:Benzamidines / Q000494:pharmacology; D002863:Chromogenic Compounds; D005174:Factor XII / Q000032:analysis*; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors; D013053:Spectrophotometry; D014105:Tosyl Compounds / Q000494:pharmacology
D001550:Benzamidines; D002863:Chromogenic Compounds; D014105:Tosyl Compounds; D005174:Factor XII; C052876:2-tosylamino-4-phenylbutyryl-4-amidinoanilide; D007610:Kallikreins